Probiotics Modulate Gut Microbiota and Improve Insulin Sensitivity in DIO Mice

J Nutr Biochem. 2017 Dec;50:16-25. doi: 10.1016/j.jnutbio.2017.08.006. Epub 2017 Aug 26.


Obesity and type 2 diabetes are characterized by subclinical inflammatory process. Changes in composition or modulation of the gut microbiota may play an important role in the obesity-associated inflammatory process. In the current study, we evaluated the effects of probiotics (Lactobacillus rhamnosus, L. acidophilus and Bifidobacterium bifidumi) on gut microbiota, changes in permeability, and insulin sensitivity and signaling in high-fat diet and control animals. More importantly, we investigated the effects of these gut modulations on hypothalamic control of food intake, and insulin and leptin signaling. Swiss mice were submitted to a high-fat diet (HFD) with probiotics or pair-feeding for 5 weeks. Metagenome analyses were performed on DNA samples from mouse feces. Blood was drawn to determine levels of glucose, insulin, LPS, cytokines and GLP-1. Liver, muscle, ileum and hypothalamus tissue proteins were analyzed by Western blotting and real-time polymerase chain reaction. In addition, liver and adipose tissues were analyzed using histology and immunohistochemistry. The HFD induced huge alterations in gut microbiota accompanied by increased intestinal permeability, LPS translocation and systemic low-grade inflammation, resulting in decreased glucose tolerance and hyperphagic behavior. All these obesity-related features were reversed by changes in the gut microbiota profile induced by probiotics. Probiotics also induced an improvement in hypothalamic insulin and leptin resistance. Our data demonstrate that the intestinal microbiome is a key modulator of inflammatory and metabolic pathways in both peripheral and central tissues. These findings shed light on probiotics as an important tool to prevent and treat patients with obesity and insulin resistance.

Keywords: Gut microbiota; Insulin sensitivity; Probiotics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue, White / immunology
  • Adipose Tissue, White / metabolism
  • Adipose Tissue, White / pathology
  • Animals
  • Appetite Regulation
  • Bifidobacterium bifidum / classification
  • Bifidobacterium bifidum / growth & development
  • Bifidobacterium bifidum / immunology
  • Bifidobacterium bifidum / isolation & purification
  • Cell Membrane Permeability
  • Diabetes Mellitus, Type 2 / etiology
  • Diabetes Mellitus, Type 2 / immunology
  • Diabetes Mellitus, Type 2 / microbiology
  • Diabetes Mellitus, Type 2 / prevention & control*
  • Diet, High-Fat / adverse effects
  • Dysbiosis / etiology
  • Dysbiosis / immunology
  • Dysbiosis / microbiology
  • Dysbiosis / prevention & control*
  • Feces / microbiology
  • Gastrointestinal Microbiome* / immunology
  • Glucose Clamp Technique
  • Insulin Resistance*
  • Intestinal Mucosa / immunology
  • Intestinal Mucosa / metabolism
  • Intestinal Mucosa / microbiology
  • Intestinal Mucosa / physiopathology*
  • Lactobacillus acidophilus / classification
  • Lactobacillus acidophilus / growth & development
  • Lactobacillus acidophilus / immunology
  • Lactobacillus acidophilus / isolation & purification
  • Lactobacillus rhamnosus / classification
  • Lactobacillus rhamnosus / growth & development
  • Lactobacillus rhamnosus / immunology
  • Lactobacillus rhamnosus / isolation & purification
  • Liver / immunology
  • Liver / metabolism
  • Liver / pathology
  • Male
  • Mice
  • Molecular Typing
  • Obesity / diet therapy*
  • Obesity / metabolism
  • Obesity / pathology
  • Obesity / physiopathology
  • Probiotics / therapeutic use*
  • Random Allocation